@The YankeeThe only way this company can sustain a share price...

@The Yankee

The only way this company can sustain a share price increase is once it has high probability (> 80%) and visibility, to being cash flow positive. This does not mean they won't need to raise again. It just means the investment thesis is viable and likely to work out for phase 1- a single FDA approval of their stem cells. From there all doors open and as others have mentioned, the low hanging fruit which can be leveraged will be the cheapest and fastest ROI in this company's long history; indication expansion and off label use.

I believe that nuanced announcement this week was that confirmation. Maybe not so nuanced based on volumes! The subsequent timing of first revenues is not only shorter than the market expected but has taken out the risks of new clinical trial outcomes, their funding and timing.

You are right. The thesis from 3,4 and 5 dollar days has not been diminished in the slightest. All trial results in the last 4 years have shown effectiveness but have not been sufficient in terms of trial design. So all indications remain live plus some new ones. Add in some medicare inflation in our target indications and dilute with share dilution, and we get back to similar share prices expectations, IMO.